Our lab has demonstrated the utility of TRAIL nanoparticles to treat a variety of cancer types in vitro (Mitchell et al., 2014), in vivo (Jyotsana et al., 2019), and in clinical samples (Ortiz-Otero et al., 2020). This evidence concerns the gene TNFSF10 and cancer.